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Abstract Gain-of-function mutations in FGFR2 cause Apert
syndrome (AS), a disease characterized by craniosynostosis
and limb bone defects both due to abnormalities in bone
differentiation and remodeling. Although the periosteum is
an important cell source for bone remodeling, its role in
craniosynostosis remains poorly characterized. We hypothe-
sized that periosteal mesenchymal stem cells (MSCs) and
fibroblasts from AS patients have abnormal cell phenotypes
that contribute to the recurrent fusion of the coronal sutures.
MSCs and fibroblasts were obtained from the periostea of 3
AS patients (S252W) and 3 control individuals (WT). We
evaluated the proliferation, migration, and osteogenic differ-
entiation of these cells. Interestingly, S252W mutation had
opposite effects on different cell types: S252W MSCs
proliferated less than WT MSCs, while S252W fibroblasts
proliferated more than WT fibroblasts. Under restrictive
media conditions, only S252W fibroblasts showed enhanced
migration. The presence of S252W mutation increased in
vitro and in vivo osteogenic differentiation in both studied
cell types, though the difference compared to WT cells was
more pronounced in S252W fibroblasts. This osteogenic
differentiation was reversed through inhibition of JNK. We
demonstrated that S252W fibroblasts can induce osteogenic
differentiation in periosteal MSCs but not in MSCs from
another tissue. MSCs and fibroblasts responded differently to
the pathogenic effects of the FGFR2S252W mutation. We
propose that cells from the periosteum have a more
important role in the premature fusion of cranial sutures
than previously thought and that molecules in JNK pathway
are strong candidates for the treatment of AS patients.
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Introduction
Apert Syndrome (AS), the most severe form of craniosynos-
tosis [1], is characterized by premature fusion of the coronal
sutures, severe syndactyly of the hands and feet and by a
range of skeletal abnormalities, including progressive joint
limitation [2–4]. This autosomal dominant syndrome is
caused by gain-of-function mutations in the FGFR2 gene.
The most prevalent mutation, accounting for approximately
65% of all AS cases, is S252W. FGFR2, by means of
alternative mRNA splicing, can be transcribed into an
epithelial and a mesenchymal isoform. Both isoforms are
tyrosine kinase receptors that bind to a specific subset of
fibroblast growth factors (FGFs) to induce a variety of cell
functions, such as cell migration, proliferation, and differen-
tiation [5]. In the presence of the S252W mutation, FGFR2
shows enhanced ligand-binding affinity to FGF2 and loses
isoform-ligand specificity for most of the other ligands [6].
This mutation affects both the epithelial and the mesenchy-
mal FGFR2 isoforms. Although most of the clinical features
of AS arise as a consequence of signaling disturbance during
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embryonic development, FGFR2S252W also interferes in post-
natal organism homeostasis. Surgical opening of the coronal
sutures is a mandatory procedure for AS patients. However,
the excessive and repetitive closure of these sutures after the
procedure (resynostosis) requires multiple interventions from
birth until adulthood [1].
It has been postulated that FGFR2S252W enhances cell
proliferation, which would account for the higher ossifica-
tion rate at the sutures [7]. However, we still do not know if
this enhanced proliferation is observed in all cell types.
Most studies have focused on murine osteoblasts harboring
the AS mutation, but both increased [8] and decreased [9]
proliferation have been observed. Studies on the effect of
FGFR2S252W on osteogenic potential have also produced
contradictory results [8–10]. Few studies have investigated
the functional effect of FGFR2S252W in human cells, which
are considerably different from murine cells in regard to
cell signaling [11–16]. We have conducted a preliminary
study in which we suggested that S252W fibroblasts have
an increased osteogenic potential [17], a finding that we
sought to replicate using in vivo models. On the other hand,
there are no studies on human AS mesenchymal stem cells
(MSC), the possible precursors of osteoblasts. The premature
suture fusion and the resynostosis process after surgical
interventions are not likely the result of alterations in one
particular cell type, such as osteoblasts, but the result of
perturbations in signaling and in interactions between
different cell types and tissues of the cranial suture
complex [18].
The cranial suture complex comprises the overlying
periosteum of the calvaria, the osteogenic fronts of the bone
plates, the intervening mesenchyme, and the underlying
dura mater. This complex allows skull deformation during
birth, expansion during brain growth and regulates the
balance between proliferation and differentiation of osteo-
genic precursors [18]. Several studies have indicated dura
mater as a crucial tissue that regulates suture patency, so it
is assumed that signaling by this tissue is deregulated in AS
patients, contributing to premature embryonic synostosis as
well as adult resynostosis [1, 19]. Remarkably, the removal
of the periosteum diminishes calcification of cranial defects
in animal models [20, 21], which highlights the importance
of the periosteum in cranial bone formation. The periosteum
contributes not only to normal bone growth, but also to
bone healing and regeneration [22, 23]. This highly
cellular tissue contains multipotent MSC, fibroblasts,
differentiated osteogenic progenitor cells and osteoblasts
[24, 25], and acts as a major source of skeletal stem cells/
progenitors during bone repair [26]. It is thus possible that
periosteal cells also have a major contribution to the
premature suture fusion in AS patients; however, their role
in this process is still poorly characterized. In addition, it is
still unknown how the different cell types from the calvarial
periosteum interact and what is the functional effect of the
FGFR2S252W mutation in these cells.
JNK (c-Jun N-terminal kinases) has been reported as
crucial for the final stage of differentiation in pre-
osteoblasts and pluripotent cells [27–30], and is considered
a critical regulator of important osteogenic differentiation
markers [30, 31]. In addition, two negative regulators of
JNK activity of the same family are associated with
craniosynostosis: DUSP6 and DUSP2. The loss of Dusp6
leads to coronal craniosynostosis in mice [32], and we have
previously reported that DUSP2 was one of the most
significant differentially expressed genes in AS periosteal
cells [17]. Therefore, JNK is an interesting candidate for the
altered osteogenic potential of S252W cells.
In view of the above, we conducted this study to access the
effect of the FGFR2S252W mutation in fibroblasts and MSCs
derived from the coronal periosteum. We examined these
cells’ proliferative capacity, motility, and osteogenic potential
and also evaluated whether there is a functional interaction
between them. Finally, we have evaluated the role of JNK in
the increased osteogenic potential of S252W fibroblasts.
Materials and Methods
Subjects
Coronal suture periosteal fibroblasts and MSCs from three
unrelated AS patients and from three age- and sex-matched
control subjects were obtained as previously described [17].
The presence of the c.934 G>C (p.S252W) mutation was
confirmed by direct DNA sequencing and expression of the
mesenchyme-specific isoform of FGFR2 in the primary
fibroblasts was examined by Western Blot and RT-PCR
[17].
Cell Culture
Periostea harvested from AS patients or control individ-
uals were split in half for fibroblast and MSC extraction.
Primary periosteal fibroblasts derived from periosteal
flaps were grown in fibroblast growth medium (DMEM
High-Glucose, 20% fetal bovine serum [FBS; GIBCO]
and 100 U/mL penicillin and 100 μg/mL streptomycin
[1% Penicillin Streptomycin; GIBCO]). Cells were
passaged at near confluency with trypsin-EDTA. MSC
cultures were obtained from finely minced periosteum
after 30 min of trypsin incubation and grown in MSC
growth medium (DMEM-F12 [Invitrogen] supplemented
with 15% FBS [GIBCO] and 1% Penicillin Streptomycin
[GIBCO]). All cells were cultured in a humidified
incubator at 37°C and 5% CO2. All tests were performed
between the third and the fifth subcultures.
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For each of the 12 cell lines (three S252W fibroblasts, three
WT fibroblasts, three S252WMSCs and threeWTMSCs), we
performed experiments in technical triplicates. For all the
experiments, we used all twelve cell lines for each condition,
the exceptions are indicated by an “n” value. Thus we tried to
ensure that the results we obtained were representative of the
biological variance seen in human patients.
Immunophenotyping
To analyze cell-surface expression of typical protein markers,
adherent cells were incubated with the following anti-human
primary antibodies: CD29-PECy5, CD31-phycoerythrin (PE),
CD45-fluorescein isothiocyanate (FITC), CD90-R-PE,
CD117-PE, and SH3 (Becton Dickinson). A total of 5,000
labeled cells were analyzed using a Guava EasyCyte flow
Cytometer running Guava ExpressPlus software (Guava
Technologies).
Cell Proliferation Analysis
A density of 4,000 cells/cm2 was plated to each well of a
12-well flat bottom plate in fibroblast growth medium.
After 24 h, when total cell adhesion was verified, the
fibroblasts were serum-starved for 24 h and MSCs for 48 h.
At the initial time point (0 h), we changed the starvation
medium (fibroblast growth medium or MSC growth
medium without FBS) for the respective cell growth
medium or starvation medium supplemented with 0.5%,
10% and 20% FBS. At the indicated times, the cells were
trypsinized and counted using Guava EasyCyte Flow
Cytometer (Guava Technologies). The experiment was
done in triplicates for each time point and cell line.
In Vitro Wound Healing Assay
We plated the cells (3×105) on 12-well culture plates
(Corning) in the respective cell growth medium. Upon
reaching 100% confluence, the fibroblasts were serum-
starved for another 24 h and MSCs for 48 h. After
starvation, a single wound was created in the center of the
cell monolayer by gentle removal of the attached cells with
a sterile plastic pipette tip. The cell layer was then scratched
with a P-200 pipette tip, the debris was removed by
washing with PBS (Phosphate Buffered Saline) and we
added fibroblast or MSC growth medium. Photographs of
the wound adjacent to reference lines scraped on the bottom
of the plate were taken using an Axio Observer microscope
under 5× field (Zeiss) at 0 h and 12 h after the wound was
done. We used the ImageJ software [33] and Adobe
Photoshop CS3 (Adobe) to analyze and calculate the
number of cells that moved into the wound. The experiment
was done in triplicates for each treatment and each cell line.
In Vitro Osteogenic Differentiation
To induce osteogenic differentiation, periosteal fibroblasts and
MSCs from three AS patients and from three controls were
plated in 24-well plates (5×103 cells/cm2) and cultured for
3 weeks in osteogenic medium (DMEM Low-Glucose, 0.5%
FBS [GIBCO], 0.1 mM dexamethasone (Sigma-Aldrich
Corp., St. Louis, MO), 50 mM ascorbate-2-phosphate
(Sigma-Aldrich), 10 mM β-glycerophosphate (Sigma-
Aldrich), and 1% Penicillin Streptomycin [GIBCO]). For
the co-culture assay, the cells were plated at the same
concentration onto 12-mm transwell inserts of 12-well plates,
0.4 μm pore size (Corning Costar). Media changes occurred
every three to 4 days. As an internal control of the
experiment, the same cells were maintained throughout the
21 days of differentiation in regular growth medium.
Alkaline phosphatase activity was assessed on the 9th
day of differentiation through a biochemical assay. The
cells were provided with phosphatase substrate (Sigma-
Aldrich) and the re-sulting p-nitrophenol was measured
colorimetrically by the use of a Multiskan EX ELISA plate
reader (Thermo Scientific) at 405 nm.
After 14 and 21 days, calcified matrix production was
analyzed by alizarin red staining and quantification was
done as previously described [34].
In Vivo Osteogenic Differentiation
A 4.5 mm in diameter ceramic scaffold (60% hydroxyapatite
and 40% of β-tricalcium phosphate; Cellceram ScaffdexTM)
was moistened with osteogenic medium and mixed with 106
human fibroblasts or MSCs. The cells attached to the
scaffold were pre-differentiated in osteogenic medium and
incubated at 37°C in 5% CO2 for 5 days.
For the in vivo differentiation we used 8 non-
immunosuppressed (NIS) Wistar rats (all males, aged
2 months, weighing a maximum of 200 g) as previously
described by our group and approved by the ethical
committee of our Institute [35]. We used a trephine bur of
4.5 mm diameter to obtain two cranial critical defects
which were made in the parietal region, lateral to the
sagittal suture, where two scaffolds were implanted per
animal, one side being filled by biomaterial alone (left
defect) and the other by the biomaterial associated with
cells (right defect). The animals were kept in ventilated
racks with standard conditions of temperature and lighting
(22°C, 12 h light cycling per day) with free access to food
and water. Four weeks after surgery, the rats were
sacrificed in a CO2 chamber. The calvaria was removed
and fixed in 10% formalin for 24 h and then decalcified in
5% formic acid for 48 h and embedded in paraffin. Slices
of 5 μm were obtained and stained with hematoxylin and
eosin.
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We analyzed three transversal 4 μm slices of the
calvaria with 10 μm of distance of each animal.
Ossification area of each defect was calculated through
Axio Vision Carl Zeiss based on 10x amplified images
obtained from Axio Observer.A1 Carl Zeiss microscope.
The percentage of the defect area that ossified at the
right side was normalized by the percentage of the
defect area that ossified at the left side, so that for each
animal we obtained 3 ratio values.
JNK Inhibitor Treatment
To test for the role of JNK in the enhanced osteogenic
potential of S252W fibroblasts, we used the reversible ATP-
competitive JNK inhibitor SP600125 (Sigma-Aldrich).
Stock solutions of at least 20 mM were made using 100%
dimethyl sulfoxide.
First, we evaluated the levels of p-JNK to confirm
the inhibition of JNK activity by SP600125, since the
inhibitor has been described to downregulate the auto-
phosphorilation activity of JNK [36]. Total protein
extracts were prepared using Phosphosafe extraction
reagent (EMD Biosciences) according to the protocol
provided by the manufacturer. The levels of P-JNK were
assessed by western blotting. The antibodies used were
anti-p-JNK (Thr183/Tyr185) Rabbit mAb (Cell Signal-
ing), anti-SAPK/JNK Rabbit mAb (Cell signaling), anti-
Rabbit IgG-HRP (Cell Signaling) and Anti-B-actin-HRP
(AbCam) (Supplementary figure 1).
During osteogenic differentiation, media were supple-
mented with 2 μM and 4 μM of the inhibitor, which
corresponds to IC50 and twice the IC50 respectively [37].
Statistical Analysis
Continuous variables were expressed by mean and standard
deviation, and the groups were compared by Student’s t-test.
A p value<0.05 was considered statistically significant. The
tests were performed using the GraphPad InStat software
(GraphPad).
Results
Characterization of the Immunophenotype
In order to certify that the results we obtained were
representative of the biological variance seen in human
patients, we performed all experiments in fibroblast or
MSC cultures from three unrelated AS patients (S252W
cells) and from three control individuals (WT cells).
Each cell culture was studied in three technical
replicates.
All cell cultures were adherent and with a fibroblast-like
appearance. We performed flow cytometry experiments
with different markers in order to characterize the immu-
nophenotype of fibroblast and MSC cultures (Table 1).
S252W and WT cells were highly positive for mesenchymal
cell markers (>85%) and negative for hematopoietic and
endothelial cell markers. These results confirm that these
cells are of mesenchymal origin.
Cell Proliferation and Cell Migration
In order to determine the effect of the FGFR2S252W
mutation in periosteal cells, we first accessed whether the
presence of the mutation altered the proliferation rates of
S252W fibroblasts and S252W MSCs. The S252W
mutation increased cell proliferation in fibroblasts at all
times of culture (24 h: p<0.001, 48 h: p<0.001; 72 h: p<
0.001) (Fig. 1a) and in different culture conditions (0.5%
FBS medium: p=0.014; 10% FBS medium: p=0.04; and
20% FBS medium: p<0.001) (Fig. 1c). On the other hand,
in MSCs, the mutation decreased cell proliferation after
72 h in MSC growth medium (72 h: p=0.002) (Fig. 1b)
and in enriched medium (20% FBS medium: p=0.004)
(Fig. 1d).
We next evaluated the effect of FGFR2S252W on cell
migration. The S252W mutation increased cell migration in
fibroblasts only in restrictive medium condition (0.5% FBS
medium: p<0.001) (Fig. 1e), but had no effect in MSCs
(Fig. 1f).
Table 1 Percentage of
positive cells for mesenchymal
(SH3, CD90, CD29),
hematopoietic (CD117 and
CD45) and endothelial (CD31)
cell lines antibodies
MSCs Fibroblasts
S252W (n=2) WT (n=2) S252W (n=4) WT (n=4)
SH3 96,32–99,78% 94,7–98,68% 88,92–98,45% 93,92–97,87%
CD90 94,92–95,52% 94,02–98,7% 89,12–99,7% 89,46–98,94%
CD29 98,48–99,12% 88,1–98,98% 85,14–99,02% 70–99,25%
CD31 <5% <5% <5% <5%
CD117 <5% <5% <5% <5%
CD45 <5% <5% <5% <5%
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In Vitro Osteogenic Differentiation
Next, we assessed the effects of the S252W mutation on
osteogenic differentiation. We performed experiments at
key points of our in vitro differentiation protocol in order to
evaluate whether the mutation plays a more prominent part
at a specific stage of osteogenic differentiation.
The ninth day of differentiation is ideal to access the
levels of alkaline phosphatase (ALP) in cultures, as in this
period there is a peak production of the enzyme. ALP
provides the phosphate needed for the production of
cellular matrix calcium. S252W fibroblasts showed 6-fold
increase in ALP activity in comparison to WT fibroblasts
(p<0.001) (Fig. 2a), while S252W MSCs had 3-fold
increase in comparison to WT MSCs (p<0.001) (Fig. 2b).
After 2 weeks in osteogenic medium, we analyzed initial
calcium deposition in the extracellular matrix (ECM)
through alizarin red staining. S252W fibroblasts showed
2.7-fold increase in ECM calcium in comparison to WT
fibroblasts (p<0.001) (Fig. 2c), while S252W MSCs had
1.5-fold increase in comparison to WT MSCs (p=0.016)
(Fig. 2d).
Finally, we evaluated concentration of ECM calcium at
the end of differentiation (21st day). S252W fibroblasts
showed a 1.7-fold increase in ECM calcium in comparison
to WT fibroblasts (p=0.002) (Fig. 2e), while S252W MSCs
had a 1.5-fold increase in comparison to WT MSCs (p<
0.001) (Fig. 2f).
In Vivo Osteogenic Differentiation
To validate these data in vivo, we performed the bilateral
cranial critical defect experiment using Wistar NIS rats as
previously described by our group [35]. At the right-side
Fig. 1 a Comparative analysis
of the proliferation of WT (from
3 individuals) and S252W (from
3 patients) fibroblasts and b WT
(from 3 individuals) and S252W
(from 3 patients) MSCs. Each
point indicates the average for
each time and each condition
and the error bars represent the
standard deviation for the
biological replicate (same
S252W or WT cell type culture
results summed). Analysis of c
WT (from 3 individuals) and
S252W (from 3 patients)
fibroblasts and d WT (from 3
individuals) and S252W (from 3
patients) MSCs when grown in
culture medium with different
FBS concentration. Each point
indicates the average of each
medium after 48 h and the error
bars represent the standard
deviation for the biological
replicate. eWound healing assay
of S252W (n=3) and WT (n=3)
fibroblasts and f and S252W
(n=3) and WT (n=3) MSCs in
high FBS and low FBS growth
medium. The bars represent the
average number of cells that
migrated toward the wound after
12 h for each condition and error
bars represent the standard
deviation for the biological
replicate (*: p<0.05, **:
p<0.01, ***: p<0.001)
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defect we introduced either S252W or WT cells associated
with biomaterial, and at the left-side defect we introduced
biomaterial only as an internal control of each animal’s
osteoregeneration. Four weeks after the surgery, the right-
side:left-side ossification ratio was 4.9 in S252W fibroblasts
and 1.9 compared to WT fibroblasts (2.6-fold higher; p=
0.036) (Fig. 2g). Likewise, this ratio was 11.8 in S252W
MSCs and 2.6 in WT MSCs (4.5-fold higher; p=0.001)
(Fig. 2h).
Interactions between Periosteal MSCs and Fibroblasts
During Osteogenic Differentiation
As shown above, we observed in vitro and in vivo that the
cellular phenotype alterations due to S252Wmutation seemed
more drastic in fibroblasts than in MSCs, and that S252W
fibroblasts are particularly more prone to osteogenic differen-
tiation. These data thus raised the question whether S252W
fibroblasts could induce osteogenic differentiation in other
cells.
Therefore, in order to test the hypothesis that a cell
population with the S252W mutation alters normal signal-
ing in adjacent cells, we used a co-culture system to
simulate the in vivo anatomic link between the fibroblasts
and MSCs in the periosteum, allowing the paracrine
signaling without physical cell interaction. S252W fibro-
blasts induced 30% more differentiation of periosteal
MSCs, whether WT (n=3) or S252W (n=2), both by
ALP assay (WT MSCs: p<0.001; S252W MSCs: p=0.037)
and alizarin red staining (vs. WT MSCs: p=0.007; vs.
S252W MSCs: p=0.016) (Fig. 3a and c). Interestingly,
S252W fibroblasts did not induce osteogenic differentiation
of MSC from another tissue, such as dental pulp stem cells
(DPSC) (Fig. 3a and c). Further, S252W MSCs and WT
MSCs exhibit no influence on the osteogenic differentiation
of S252W fibroblasts (Fig. 3b and d).
Potential Molecule Involved in Altered Fibroblast
Osteogenic Potential
To assess whether JNK plays a role in the increased
osteogenic potential of S252W fibroblasts, we treated
S252W fibroblasts with 2 μM (IC50) [37] and 4 μM (twice
IC50) of SP600125, a JNK phosphorylation inhibitor,
during osteogenic differentiation. We observed a lower
ALP activity as we increased the concentration of
SP600125 (untreated vs. +2 μM SP600125: p=0.025;
+2 μM SP600125 vs. +4 μM SP600125: p=0.014). This
effect was also observed by alizarin red staining (untreated
vs. +2 μM SP600125: p=0.006; untreated vs. +4 μM
SP600125: p=0.003) (Fig. 4a and b). At the maximal
inhibition of JNK (4 μM), ALP activity of S252W
fibroblast and WT fibroblasts were equivalent. Therefore,
inhibition of JNK activity rescued the increased osteogenic
potential of S252W fibroblasts.
Discussion
The only treatment available nowadays for AS patients is
surgical intervention, which consists of artificial recon-
struction of the coronal sutures [38]. Nevertheless, post-
surgical ossification of the sutures (resynostosis) is frequent
and any surgical treatment for craniosynostosis during
childhood is considered a procedure to delay but not to
prevent synostosis [1]. To understand the cause and prevent
resynostosis of the sutures so that they remain open during
the growth phase of the individual, it is important to
identify the main molecules and mechanisms involved in
this process. This knowledge can contribute to a better
management of the affected child, enhancing their life
quality. Bone regeneration studies have pointed to the
periosteum as a significant contributor to the ossification
process [22, 23], not only through molecular signaling, but
also by providing osteoprogenitor cells [26]. Despite the
periosteum’s possible contribution to premature suture
ossification in AS and other craniosynostosis, the mecha-
nism by which FGFR2 gain-of-function mutations achieve
this effect is not clear. Unbalanced FGF signaling can
accelerate proliferation, migration, and differentiation in
osteoprogenitor cells from the periosteum and contribute to
resynostosis, though this process continues to be poorly
understood, particularly in AS patients. Study of cells
derived from the periosteum of the AS patients can help to
elucidate these questions, as we can compare the effect of
the mutation in different cell types from the same niche.
This could be of particular relevance considering that cell
signaling can be different between mice and humans, and
that the range of phenotypic effects of a mutation is not
always the same in both [13–16]. Here we successfully
established fibroblasts and MSCs cell cultures from the
periosteum of both AS and control individuals. In accor-
dance to the literature [38], we were not able to distinguish
these two cell types based on morphology and positive
staining for mesenchymal cell markers. However, the
Fig. 2 S252W and WT fibroblasts and MSCs (all conditions: n=3) in
response to osteogenic medium during different phases of osteogenic
differentiation. a, b Analysis of alkaline phosphatase activity on the
9th day of osteogenic differentiation; c, d alizarin red staining
quantification at the 14th day of differentiation; e, f alizarin red
staining quantification at the 21st day of osteogenic differentiation.
The columns represent the absorbance at wavelength indicated for
each condition and error bars represent the standard deviation for the
biological replicate. g Percentage of ossification area of calvarial
defects with WT or S252W fibroblasts in rats 4 weeks after surgery.
h Percentage of ossification area of calvarial defects with WT or
S252W MSCs in rats 4 weeks after surgery (*: p<0.05; **: p<0.01;
***: p<0.001)

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positive bone differentiation seen in WT MSCs but not in
WT fibroblasts confirms that our protocols allow for the
establishment of two distinct cell populations, as we have
shown in our previous reports [17, 39].
The S252W mutation enhanced cell proliferation in
fibroblasts, even in critical culture conditions, such as 0.5%
FBS medium, but it had a negative effect on MSCs in 20%
FBS culture environment. Literature data regarding the
presence of FGFR2S252W and cell proliferation are controver-
sial. Some studies that investigated human periosteal fibro-
blasts [17], murine osteoblasts [8], murine stem cells [40], or
calvarial cells during embryonic sutures formation in murine
AS models [41, 42] point to the FGFR2S252W mutation as
responsible for increasing cell proliferation. Interestingly, the
murine MSCs with FGFR3 mutation proliferate less than the
wild type cells [43]. These comparative analyses are complex,
as the experiments have not only included different cell types
but also cells from different species and from different niches.
Therefore, although we cannot rule out differences in the
protocols used, our results suggest that the effect of the
FGFR2S252W mutation on cell proliferation might depend
both on the tissue, niche of origin, and cell type under
Fig. 3 Effects of interaction
between periosteal MSCs and
fibroblasts. a Analysis of alka-
line phosphatase activity on the
9th day and c alizarin red stain-
ing at the 21st day of osteogenic
differentiation of S252W MSCs
(n=2), WT MSCs (n=2) and
WT DPSC (n=1) co-cultured
with fibroblasts with or without
the mutation in the presence of
osteogenic medium. b Analysis
of alkaline phosphatase activity
on the 9th day and d alizarin red
staining at the 21st day of
osteogenic differentiation of
S252W fibroblast (n=1) co-
cultured with MSCs with or
without the mutation in the
presence of osteogenic medium.
The columns represent the
absorbance at wavelength indi-
cated for each condition and
error bars represent the standard
deviation for the biological
replicate (*: p<0.05, **:
p<0.01, ***: p<0.001)
Fig. 4 Effects of JNK inhibition
in periosteal S252W (n=2) and
WT (n=2) fibroblasts. a Analy-
sis of alkaline phosphatase
activity on the 9th day of oste-
ogenic differentiation. b Alizarin
red staining quantification at the
21st day of osteogenic differen-
tiation. The columns represent
the absorbance at wavelength
indicated for each condition and
error bars represent the standard
deviation for the biological
replicate (*: p<0.05, **:
p<0.01, ***: p<0.001)
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analysis, which would explain at least in part the controversy
in the literature.
Through the wound healing assay, we have shown that
FGFR2S252W has an effect on the migratory property of
fibroblasts, but not of MSCs. This effect on the fibroblasts,
however, was dependent on the availability of FBS, a
culture medium supplement that provides not only growth
factors, but also cellular growth inhibitors [44]. It was
previously reported that FGFR2S252W has enhanced affinity
to different FGFs [45], therefore, the altered S252W cell
proliferation and cell migration in response to different FBS
concentrations suggests that FBS contains growth stimulat-
ing FGFs to which S252W fibroblasts are more sensitive to,
and FGFs that in high concentration inhibit migration of
S252W fibroblasts. It is possible that during embryonic and
even post-natal development, atypical cell responses are
dependent on which FGF is available at that period.
Regarding the osteogenic potential, we found that
FGFR2S252W induces increased osteogenic differentiation
in both cell types under study, especially at the early stages
of the in vitro process. We were able to confirm these
results in vivo using non-immunosuppressed rats and
human cells, as an increased ossification rate was observed
for both fibroblasts and MSCs harboring the FGFR2S252W
mutation as compared to corresponding WT cells. These
results thus confirm our preliminary work on S252W
fibroblasts [13] which showed that the FGFR2S252W
mutation confers a new function to these cells. In addition,
our results for MSCs, the osteoblast precursors, are in
agreement with most of the literature, ranging from studies
with murine stem cells to human pre-osteoblasts transfected
with FGFR2S252W, which showed that the FGFR2S252W
mutation enhances osteogenic potential [8, 9, 40, 41, 46].
A dynamic system based on integrated signals between
stem cells and cells from their surrounding niche, such as
fibroblasts, is necessary to maintain proper tissue physiology
[47]. Thus, we judged it necessary to evaluate the effect of
S252W fibroblasts on the MSCs, the expected osteoblast
precursors. Interestingly, our co-culture assay showed that
the presence of S252W fibroblasts promotes osteogenic
differentiation of both S252W and WT periosteal MSCs. In
addition, S252W fibroblasts did not induce osteogenic
differentiation in DPSC, which suggests that the cells we
used must still harbor regulatory network programs that are
specific to the tissue from which they are extracted and that
are not erased in cell culture.
The increased osteogenic potential of S252W fibroblasts
seems to be mediated by JNK, since JNK inhibition
reverted this phenotype. Shukla et al. demonstrated that
ERK (extracellular-signal-regulated kinase) is directly
involved in the craniosynostosis in a Fgfr2+/S252W mouse
[48]. Futhermore, ERK indirectly increases JNK activity
[49]. Our findings thus suggest that ERK-JNK pathway is
also disturbed in human AS patients and that a key
molecule involved in craniosynostosis lies downstream to
ERK and JNK. Altogether, we propose that identifying this
key molecule might have a better therapeutic potential in
the surgical treatment of AS patients than ERK and JNK
inhibitors, as inhibition of either molecule leads to severe
side effects as both are involved in important signaling
pathway in the whole organism. We cannot rule out the
possibility that other MAPKs, such as p38, downstream to
FGFR activation might be responsible for the increased
osteogenic potential in the S252W fibroblasts, as these
molecules have been shown to have enhance activation in
Apert mouse models [41, 43, 48, 50–54].
Fig. 5 In the periosteum (pink)
overlying the suture (brown),
fibroblasts (green cells) and
MSCs (blue cells) have similar
cell growth and cell migration
rates. However, fibroblasts
exhibit low while MSCs show
higher osteogenic potential
(left). The FGFR2S252W muta-
tion has a positive effect on both
proliferation and migration of
fibroblasts, and a negative effect
on MSC proliferation. It has no
consequence on MSCs migra-
tion. Both cell types have
enhanced osteogenic differentia-
tion and S252W fibroblasts
show positive influence on
MSCs differentiation. Inhibition
of JNK phosphorylation by
SP600125 can null the effect of
the mutation over osteogenic
differentiation of fibroblasts
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Based on our results, we propose that the FGFR2S252W
mutation confers a most pronounced gain-of-function in
fibroblast cells. Of the cell phenotypes evaluated, the most
strikingly altered one is their increased osteogenic potential.
This represents an acquired new function for fibroblasts,
apparently mediated by JNK pathway. It has been
suggested that the premature suture fusion in S252W cells
is a result of excessive cell proliferation [7]. In the present
study, FGFR2S252W mutation leads to increased prolifera-
tion, migration, and osteogenic potential of both fibroblasts
and MSCs. Therefore, the premature ossification process
might result from a more complex mechanism than only
alteration of the proliferative capacity. Further, we show
that fibroblasts enhance the osteogenic potential of MSCs
of the same niche. These results allow us to suggest that
periosteum cells might contribute to premature suture
fusion in these patients (Fig. 5), a characteristic that has
previously been attributed to dura mater [49]. To better
understand the molecular mechanisms underlying our
findings, it is crucial to identify molecules secreted by
S252W fibroblasts that may contribute to intensify osteo-
genic differentiation in other cells and whether they are
related to the JNK pathway. These molecules could lead to
the identification of candidate drugs that could ameliorate
the surgical prognosis of AS patients.
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